OC.09.3 INFLIXIMAB DOSE-REDUCTION IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS IN PROLONGED DEEP REMISSION: POTENTIAL IMPLICATIONS ON DE-ESCALATION STRATEGIES IN A REAL LIFE CLINICAL SETTING WITHOUT A THERAPEUTIC DRUG MONITORING (TDM) APPROACH. (25th March 2019)